Clinical Trials Browser

Interventional × Neoplasms × lenvatinib × Clear all

NCT05064280 2026-04-16

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Phase 2 Recruiting

Brain Neoplasms, Neoplasms

NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Phase 1/2 Active not recruiting

GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05081180 2026-01-23

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Phase 1 Active not recruiting

Neoplasms, Central Nervous System Neoplasms

NCT05273554 2026-01-12

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1 Active not recruiting

Adenocarcinoma, Neoplasms

NCT03564691 2025-10-07

MK-4830-001

Phase 1 Completed

Neoplasms

NCT05822752 2025-08-14

LIVIGNO-1

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT06161558 2025-07-16

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Neoplasms

NCT02720068 2025-05-30

MK-4280-001

Phase 1 Completed

481 enrolled 36 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT04976634 2025-04-06

MK-6482-016

Phase 2 Active not recruiting

Neoplasms

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02640508 2024-05-09

Eribulin and Lenvatinib in Advanced Solid Tumors

Phase 2 Completed

29 enrolled 13 charts

Neoplasms

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT05767684 2023-08-25

Neoantigen Derived DCs as Cancer Treatment

Phase 1 Unknown

Neoplasms

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase 1/2 Completed

357 enrolled 28 charts 2 FDA

Neoplasms

NCT02432274 2023-07-11

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Phase 1/2 Completed

117 enrolled 32 charts

Neoplasms, Osteosarcoma

NCT00121719 2023-06-22

An Open Label Dose Escalation Study Of E7080

Phase 1 Completed

82 enrolled 34 charts

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms

NCT01268293 2023-06-22

A Study of E7080 in Subjects With Solid Tumor

Phase 1 Completed

9 enrolled 6 charts

Neoplasms

NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Phase 2 Recruiting

GastrointestinalGynecologic

NCT05322187 2022-04-11

sPLENTY-pc

Phase 2/3 Unknown

Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Phase 3 Completed

954 enrolled 19 charts 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT02686164 2019-08-28

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

Phase 1 Completed

51 enrolled 11 charts

Neoplasms

NCT02846766 2018-08-02

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

Phase 2 Withdrawn

Acrocephalosyndactylia, Neoplasms

NCT00280397 2016-10-07

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

Phase 1 Completed

27 enrolled 8 charts

Neoplasms

NCT00121680 2015-12-11

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

Phase 1 Completed

Melanoma, Neoplasms

NCT00832819 2015-04-30

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

28 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT01240408 2015-03-04

E7080 Food Effect Study in Healthy Subjects

Phase 1 Completed

Neoplasms